# Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

> **NCT03630081** · PHASE3 · UNKNOWN · sponsor: **Wockhardt** · enrollment: 1004 (estimated)

## Conditions studied

- Complicated Urinary Tract Infection
- Acute Pyelonephritis

## Interventions

- **DRUG:** WCK 4282 (FEP-TAZ) 4 g
- **DRUG:** Meropenem
- **DRUG:** ciprofloxacin 500 mg Optional Oral Switch
- **OTHER:** Infusion of normal saline

## Key facts

- **NCT ID:** NCT03630081
- **Lead sponsor:** Wockhardt
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01
- **Primary completion:** 2026-01
- **Final completion:** 2026-02
- **Target enrollment:** 1004 (ESTIMATED)
- **Last updated:** 2023-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03630081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03630081, "Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT03630081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*